Fact-checked by Grok 2 weeks ago

Vascular endothelial growth factor A

Vascular endothelial growth factor A (VEGF-A) is a homodimeric glycoprotein and key member of the platelet-derived growth factor (PDGF) family of signaling proteins that primarily regulates angiogenesis—the formation of new blood vessels from pre-existing vasculature—as well as vascular permeability and endothelial cell survival.^[1] Encoded by the VEGFA gene on human chromosome 6p21.1, VEGF-A exists in multiple isoforms generated by alternative splicing of eight exons, with the most prevalent being VEGF-A165, which features a central receptor-binding domain and a C-terminal heparin-binding domain essential for its interactions.^[2] Originally identified in 1983 as vascular permeability factor (VPF) from tumor cell supernatants and cloned in 1989, VEGF-A binds to tyrosine kinase receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) on endothelial cells, with VEGFR-2 mediating the majority of its pro-angiogenic signals through pathways involving phospholipase Cγ, PI3K/Akt, and MAPK/ERK.^[2]^[1] Beyond angiogenesis, VEGF-A plays critical roles in embryonic development, where its expression begins around embryonic day 7 in mice and is indispensable for vasculogenesis, as Vegfa knockout leads to embryonic lethality due to impaired vascular development.^[2] It also contributes to physiological processes like wound healing, female reproductive functions (e.g., corpus luteum vascularization), and bone formation, while being upregulated by hypoxia-inducible factor 1 (HIF-1) in low-oxygen conditions.^[3] In pathology, VEGF-A drives pathological angiogenesis in conditions such as cancer—where it supports tumor growth and metastasis by enhancing vascular supply—age-related macular degeneration (AMD), diabetic retinopathy, and rheumatoid arthritis.^[4]^[5] Anti-VEGF therapies, including monoclonal antibodies like bevacizumab (Avastin) and ranibizumab (Lucentis), have revolutionized treatment for cancer, AMD, and diabetic retinopathy by inhibiting VEGF-A binding to its receptors, though challenges like resistance and systemic side effects persist; VEGF-A's role in rheumatoid arthritis suggests potential but therapies are not yet clinically established.^[3]

Gene and Structure

VEGFA Gene

The VEGFA gene is located on the short arm of human chromosome 6 at position 6p21.1 and spans approximately 16 kb of genomic DNA, consisting of eight exons and seven introns.^[1]^[6]^[7] Alternative splicing of the VEGFA pre-mRNA, particularly involving exons 6 and 7, generates the principal isoforms (VEGF121, VEGF165, VEGF189, VEGF206) that differ in their C-terminal heparin-binding domains. Further diversification into pro-angiogenic (VEGFAxxxa) and anti-angiogenic (VEGFAxxxb) variants occurs through alternative splicing at exon 8, with the balance influenced by cellular conditions.^[7]^[8]^[9] Transcription of the VEGFA gene is primarily regulated by the hypoxia-inducible factor 1-alpha (HIF-1α), which binds to hypoxia response elements (HREs) within the gene's promoter region to induce expression under low-oxygen conditions.^[10]^[11]^[12] VEGFA is expressed in various cell types, including endothelial cells, podocytes, macrophages, and tumor cells, with expression markedly upregulated in hypoxic environments such as those found in ischemic tissues or solid tumors.^[13]^[14]^[15] The VEGFA gene exhibits strong evolutionary conservation across mammalian species, with the orthologous Vegfa gene in mice serving as a key model for functional studies; targeted knockout of Vegfa in mice results in embryonic lethality around days 8.5 to 9.5 due to severe vascular developmental defects, including impaired endothelial cell proliferation and blood vessel formation.^[16]^[17]^[18]

Protein Structure

Vascular endothelial growth factor A (VEGF-A) is a secreted, disulfide-linked homodimeric glycoprotein with a molecular weight ranging from 34 to 42 kDa, formed by two noncovalently associated monomers each containing approximately 121 to 206 amino acids, depending on the isoform.^[1]^[19] The protein's dimeric nature is stabilized by two intermolecular disulfide bonds between cysteine residues 51 and 60 on adjacent monomers, while each monomer features a central platelet-derived growth factor (PDGF)-like domain that adopts a cystine-knot fold.^[19]^[4] The cystine-knot motif in the PDGF-like domain is defined by six conserved cysteine residues that form three intramolecular disulfide bonds, providing structural rigidity essential for ligand-receptor interactions and overall stability. Two additional cysteine residues (Cys51 and Cys60) form intermolecular disulfide bonds that stabilize the homodimer.^[20]^[4]^[21] Longer isoforms of VEGF-A include a C-terminal heparin-binding domain rich in basic amino acids, which mediates interactions with extracellular matrix components such as heparan sulfate proteoglycans, thereby modulating bioavailability and localization.^[4] Additionally, VEGF-A undergoes post-translational glycosylation, including an N-linked site at asparagine 74 (precursor numbering) and potential O-linked modifications, which enhance solubility, protect against proteolysis, and influence bioactivity.^[22]^[23] The three-dimensional structure of VEGF-A has been elucidated through X-ray crystallography, with the Protein Data Bank entry 1FLT providing a 1.7 Å resolution model of VEGF165 in complex with domain 2 of the Flt-1 receptor (VEGFR-1).^[24] This structure highlights the receptor-binding interfaces primarily on the N-terminal region of the PDGF-like domain, involving loops 1 (residues 42–50), 2 (residues 61–66), and 3 (residues 79–93), as well as adjacent β-strands, which form polar and hydrophobic contacts critical for high-affinity binding to VEGF receptors.^[24]^[4] These structural features underscore VEGF-A's role as a symmetric homodimer capable of bivalent engagement with cell-surface receptors.

Isoforms

Vascular endothelial growth factor A (VEGF-A) exists in multiple isoforms generated through alternative splicing of the VEGFA pre-mRNA, primarily differing in their C-terminal regions which affect heparin binding, extracellular matrix (ECM) association, and bioactivity. The major human isoforms include VEGF121, VEGF165, VEGF189, and VEGF206, each with distinct biochemical properties. VEGF121 is a non-heparin-binding, acidic protein that remains freely diffusible without significant ECM retention.^[25] In contrast, VEGF165 exhibits moderate heparin binding, allowing partial ECM association and making it the predominant isoform in most human tissues.^[25] VEGF189 and VEGF206 are highly basic, with strong heparin and ECM binding, resulting in predominant localization to the ECM and limited diffusion.^[25] These differences in binding affinity influence their spatiotemporal distribution and functional roles in angiogenesis.^[26] VEGF-A isoforms are further diversified into pro-angiogenic (VEGFxxxa) and anti-angiogenic (VEGFxxxb) variants, arising from alternative splicing at exon 8, which alters the C-terminal helix and modulates receptor affinity. Pro-angiogenic isoforms like VEGF165a promote endothelial cell proliferation and vessel formation through high-affinity binding to VEGF receptors (VEGFRs).^[27] Conversely, anti-angiogenic isoforms such as VEGF165b inhibit these processes by competitively binding VEGFR2 with lower affinity and failing to activate downstream signaling effectively.^[28] This balance between VEGFxxxa and VEGFxxxb isoforms regulates net angiogenic potential in tissues.^[28] Tissue-specific expression patterns contribute to isoform functionality. VEGF121 is prominently expressed in embryonic tissues, supporting early vascular development through its diffusible nature.^[29] VEGF165 predominates in adult vasculature and is upregulated in tumors, facilitating localized angiogenesis.^[30] VEGF189 shows lower expression in most adult tissues but contributes to ECM-bound signaling in specific contexts.^[31] Functional differences among isoforms arise from their interactions with co-receptors and ECM. VEGF165 is optimal for angiogenesis due to its ability to bind neuropilin-1 (NRP1), enhancing VEGFR2 signaling and endothelial cell migration.^[23] Shorter isoforms like VEGF121 exhibit reduced potency in inducing vascular permeability compared to VEGF165, owing to the absence of heparin-binding domains that stabilize receptor complexes.^[23] In mice, homologous isoforms Vegf120, Vegf164, and Vegf188 correspond to human VEGF121, VEGF165, and VEGF189, respectively, and have been studied using isoform-specific knock-in models. Vegf120/120 mice display severe defects in vascular outgrowth and patterning, particularly in retinal venules, due to the lack of ECM-bound isoforms.^[32] Vegf188/188 mice show normal venular patterning but reduced arteriolar development and increased vessel density with thinner walls.^[32] Vegf164/164 mice exhibit balanced retinal angiogenesis similar to wild-type, highlighting the intermediate role of this isoform.^[32] These studies reveal that isoform-specific localization provides spatially restricted cues for vascular branching and arterial-venous patterning.^[33]

Biological Functions

Angiogenesis and Vasculogenesis

Vascular endothelial growth factor A (VEGF-A) plays a central role in stimulating endothelial cell proliferation, migration, and tube formation, primarily through activation of VEGF receptor 2 (VEGFR2). This signaling promotes the growth and reorganization of endothelial cells into vascular structures during angiogenesis. Specifically, binding of VEGF-A to VEGFR2 triggers intracellular pathways that enhance cell survival and motility, enabling endothelial cells to form new tubular networks essential for vessel assembly.^[34]^[35] VEGF-A is essential for both embryonic vasculogenesis, the de novo assembly of blood vessels from mesodermal precursors, and angiogenesis, the sprouting of new vessels from existing vasculature. Inactivation of a single VEGF-A allele in mice leads to embryonic lethality between days 11 and 12, characterized by impaired development of blood islands and vascular networks, underscoring its non-redundant role in these processes. Heterozygous VEGF-A deficiency results in abnormal blood vessel formation, with reduced endothelial cell proliferation and disorganized vascular patterning, confirming its necessity for proper embryonic vascularization.^[36]^[37] Paracrine signaling of VEGF-A from pericytes and smooth muscle cells to endothelial cells further supports vessel maturation and survival during angiogenesis. Differentiated pericytes secrete cell-associated VEGF-A that acts in a juxtacrine or paracrine manner to stabilize nascent vessels and promote endothelial integrity. This interaction ensures coordinated vessel remodeling, where VEGF-A from perivascular cells enhances endothelial responses to maintain vascular homeostasis. In wound healing, VEGF-A is upregulated post-injury in keratinocytes, macrophages, and other cells at the wound site, driving the formation of granulation tissue through induced angiogenesis. Hypoxia in the wound microenvironment further elevates VEGF-A expression via hypoxia-inducible factor-1, facilitating endothelial invasion into the provisional matrix to support tissue repair.^[38]^[39] Quantitative aspects of VEGF-A function include its concentration gradients, which guide the extension of filopodia from endothelial tip cells during sprouting angiogenesis. These gradients polarize tip cell behavior, directing filopodial protrusions toward higher VEGF-A levels to initiate and orient vascular sprouts in tissues like the postnatal retina.^[40]

Vascular Permeability and Non-Vascular Roles

Vascular endothelial growth factor A (VEGF-A) plays a critical role in modulating vascular permeability by inducing structural changes in endothelial cells, distinct from its primary angiogenic functions. It promotes the formation of endothelial fenestrations, which are transcellular pores that facilitate the selective passage of molecules across the vessel wall, thereby enhancing plasma extravasation in response to physiological demands.^[41] Additionally, VEGF-A triggers the disassembly of adherens junctions through tyrosine phosphorylation of VE-cadherin, a key component of endothelial cell-cell contacts, leading to increased vascular leakiness without necessarily promoting long-term vessel proliferation.^[42] This mechanism allows for rapid adjustments in barrier function during tissue remodeling. In female reproduction, VEGF-A is essential for ovarian follicle vascularization, where it supports the development of a permeable vascular network around growing follicles to supply nutrients and hormones.^[43] It also drives endometrial angiogenesis, ensuring adequate blood supply for implantation and placental formation by increasing vessel permeability and branching in the uterine lining.^[44] Beyond vascular tissues, VEGF-A exerts non-vascular functions in various organs. In the nervous system, it provides neuroprotection by stabilizing the blood-brain barrier and promoting neuronal survival under stress, such as hypoxia, through direct receptor-mediated effects on neural cells.^[45] In bone formation, VEGF-A directly stimulates osteoblast differentiation, enhancing mineralization and matrix production independent of its angiogenic role.^[46] Similarly, in the kidney, VEGF-A contributes to glomerular repair by maintaining endothelial integrity and supporting podocyte-endothelial crosstalk to restore filtration barrier function after injury.^[47] VEGF-A also contributes to inflammation by recruiting monocytes to sites of immune response, primarily through binding to VEGFR1 on these cells, which facilitates their migration and activation without direct involvement in vessel growth.^[48] During embryonic development, VEGF-A supports hematopoiesis in the yolk sac by promoting the survival and differentiation of hematopoietic progenitors in this early vascular niche.^[49] It further aids heart valve formation by regulating endothelial-to-mesenchymal transition in the endocardial cushions, ensuring proper valvular remodeling.^[50]

Molecular Interactions and Signaling

Receptors and Co-Receptors

Vascular endothelial growth factor A (VEGF-A) exerts its effects primarily through binding to two main receptor tyrosine kinases: VEGF receptor 1 (VEGFR1, also known as Flt-1) and VEGF receptor 2 (VEGFR2, also known as KDR or Flk-1). VEGFR1 binds VEGF-A with high affinity, characterized by a dissociation constant (Kd) of approximately 10–20 pM, but features weak intrinsic tyrosine kinase activity, often serving as a decoy receptor that sequesters VEGF-A to regulate its bioavailability and prevent excessive signaling through other receptors. In comparison, VEGFR2 exhibits lower binding affinity for VEGF-A (Kd ≈ 100–750 pM) yet possesses robust kinase activity, making it the principal mediator of VEGF-A-induced endothelial cell proliferation, migration, and survival during angiogenesis. Co-receptors play a critical role in modulating VEGF-A signaling by enhancing receptor-ligand interactions and complex formation. Neuropilin-1 (NRP1) and neuropilin-2 (NRP2), transmembrane proteins lacking intrinsic kinase activity, act as co-receptors that bind specific VEGF-A isoforms, such as VEGF165, and bridge them to VEGFR2 to amplify signaling efficiency. NRP1 binds VEGF165 with a Kd of approximately 100–300 pM, thereby increasing the overall affinity of VEGF-A for VEGFR2 and facilitating the formation of ternary complexes that promote endothelial cell responses.^[51] NRP2 functions similarly but with somewhat reduced affinity (Kd ≈ 700 pM for VEGF165), contributing to isoform-specific signaling modulation. Additionally, heparan sulfate proteoglycans within the extracellular matrix serve as accessory co-receptors, binding VEGF-A and stabilizing its interactions with VEGFRs and NRPs to fine-tune localization and presentation on cell surfaces.^[52] Ligand binding by VEGF-A induces dimerization of these receptors, a key step in activation. VEGF-A, as a dimeric ligand, promotes the formation of VEGFR homodimers (particularly VEGFR2-VEGFR2) or heterodimers (VEGFR1-VEGFR2), which brings the intracellular kinase domains into proximity for subsequent autophosphorylation.^[53] This process is isoform-dependent; for instance, the shorter isoform VEGF121 binds solely to VEGFR1 and VEGFR2 without requiring NRPs, whereas longer isoforms like VEGF165 engage NRPs for enhanced dimerization and signaling potency.^[54] Expression patterns of these receptors influence their functional roles. VEGFR2 is predominantly expressed on vascular endothelial cells, where it orchestrates angiogenic processes in response to VEGF-A. VEGFR1 shows broader expression, including on endothelial cells, monocytes/macrophages, and trophoblast cells, enabling its involvement in inflammation, immune responses, and placental development.^[55]^[56]

Downstream Pathways

Upon binding of vascular endothelial growth factor A (VEGF-A) to its primary receptor VEGFR2, the receptor undergoes autophosphorylation at specific tyrosine residues, initiating multiple intracellular signaling cascades that regulate endothelial cell behavior.^[57] These pathways include the phospholipase Cγ (PLCγ)-inositol trisphosphate (IP3) axis, the phosphoinositide 3-kinase (PI3K)-Akt pathway, and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) cascade, each activated via distinct phosphorylation sites on VEGFR2.^[57] Phosphorylation of VEGFR2 at tyrosine 1175 (Y1175) recruits and activates PLCγ, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate IP3 and diacylglycerol (DAG). IP3 subsequently triggers intracellular calcium (Ca²⁺) release from the endoplasmic reticulum, promoting endothelial permeability and cytoskeletal dynamics essential for vascular remodeling.^[57] In parallel, phosphorylation at Y951 enables recruitment of the adaptor protein T-cell-specific adaptor (TSAd), which facilitates PI3K activation and contributes to Src-mediated signaling that enhances vascular permeability.^[57] The PI3K-Akt pathway, further amplified via Y951 and associated sites like Y801 and Y1214, phosphorylates Akt, promoting endothelial cell survival by inhibiting apoptosis and stimulating nitric oxide (NO) production through endothelial nitric oxide synthase (eNOS) activation.^[57] This pathway is critical for maintaining endothelial integrity under hypoxic or stress conditions.^[58] The MAPK/ERK pathway is activated primarily through VEGFR2 phosphorylation at Y1059, which supports full kinase activity and recruits adaptor proteins like Grb2-Sos, leading to Ras-Raf-MEK-ERK sequential activation. This cascade drives endothelial proliferation and migration by upregulating transcription factors such as c-Fos and Elk-1.^[57] In contrast, VEGFR1, upon VEGF-A binding, primarily activates PI3K via sites like Y1169 and Y1213, fostering chemotaxis and directed migration in endothelial and monocytic cells without inducing robust proliferation signals.^[59] VEGF-A signaling exhibits crosstalk with cell adhesion molecules, where VEGFR2 complexes with integrins (e.g., αvβ3 and α5β1) and VE-cadherins to reorganize the actin cytoskeleton. Integrin engagement amplifies VEGFR2 autophosphorylation and focal adhesion kinase (FAK) activation, facilitating lamellipodia formation and migratory persistence, while VE-cadherin at adherens junctions modulates Src activity to fine-tune junctional stability during cytoskeletal rearrangements.^[60] Negative regulation of these pathways occurs through mechanisms such as PTEN-mediated dephosphorylation of PIP3, which antagonizes PI3K-Akt signaling and limits excessive endothelial proliferation and survival.^[61] Additionally, soluble VEGFR1 (sFlt-1) sequesters VEGF-A extracellularly, preventing receptor activation and thereby attenuating downstream cascades to maintain angiogenic homeostasis.^[62]

Clinical Significance

Pathological Involvement

Vascular endothelial growth factor A (VEGF-A) dysregulation contributes to a wide array of pathological conditions by promoting excessive angiogenesis, increasing vascular permeability, and disrupting normal vascular homeostasis. In pathological states, elevated VEGF-A levels often drive aberrant vessel formation and leakage, exacerbating tissue damage and disease progression, in contrast to its regulated role in physiological vascular development. In cancer, VEGF-A is a primary mediator of tumor angiogenesis, enabling the growth and metastasis of malignant cells by inducing the proliferation and migration of endothelial cells to form a supportive vascular network within the tumor stroma. This process allows tumors to evade hypoxia and acquire essential nutrients, with VEGF-A overexpression observed in the majority of solid tumors, including colorectal and lung cancers.^[63] VEGF-A also facilitates metastasis by enhancing tumor cell intravasation into the bloodstream through leaky vessels and promoting pre-metastatic niche formation in distant organs.^[64] In ocular diseases, VEGF-A drives pathological neovascularization, leading to vision-threatening complications. In diabetic retinopathy, elevated VEGF-A levels in the retina promote the growth of fragile new vessels and increase vascular permeability, resulting in retinal hemorrhages, macular edema, and potential blindness.^[65] Similarly, in age-related macular degeneration (AMD), particularly the neovascular form, VEGF-A induces choroidal neovascularization, where abnormal vessels leak fluid and blood into the macula, causing central vision loss.^[66] Cardiovascular diseases also involve dysregulated VEGF-A signaling. In atherosclerosis, increased VEGF-A expression contributes to plaque progression and instability by promoting neovascularization, inflammation, and endothelial activation in arterial walls.^[67] Conversely, excessive VEGF-A in heart failure exacerbates edema by increasing vascular permeability, leading to fluid accumulation in tissues and worsening cardiac decompensation.^[68] Beyond these, VEGF-A dysregulation manifests in other conditions. In preeclampsia, elevated soluble fms-like tyrosine kinase-1 (sFlt-1) sequesters VEGF-A, reducing its bioavailability and causing systemic endothelial dysfunction, hypertension, and proteinuria.^[69] In rheumatoid arthritis, VEGF-A stimulates synovial angiogenesis, supporting chronic inflammation and pannus formation that erodes joint structures.^[70] In POEMS syndrome, markedly elevated serum VEGF-A levels correlate with disease severity, contributing to vascular permeability and multi-organ involvement.^[71] Genetic variations in the VEGFA gene further link it to vascular pathologies. Single nucleotide polymorphisms (SNPs) in the VEGFA promoter region, such as rs699947 and rs2010963, are associated with increased risk of retinopathy, including diabetic retinopathy, by altering VEGF-A expression levels and influencing disease susceptibility.^[72] Mutations in VEGFA are rare but have been implicated in congenital vascular malformations, such as left ventricular outflow tract obstruction and other anomalies, disrupting normal vascular development.^[73] Recent studies as of 2024 highlight VEGF-A's role in cerebral small vessel disease (cSVD), where elevated levels contribute to blood-brain barrier disruption, endothelial dysfunction, and increased risk of lacunar strokes and cognitive impairment.^[74]

Therapeutic Applications

Vascular endothelial growth factor A (VEGF-A) modulation has revolutionized therapeutic strategies in conditions characterized by aberrant angiogenesis, with anti-VEGF agents forming the cornerstone of treatments for cancers and ocular disorders.^[57] These agents inhibit VEGF-A signaling to suppress pathological vessel growth, demonstrating efficacy in clinical settings where VEGF-A overexpression drives disease progression.^[75] In oncology, anti-VEGF therapies are integrated into regimens to starve tumors of necessary blood supply, while in ophthalmology, they target neovascularization to preserve vision.^[76] Bevacizumab (Avastin), a recombinant humanized monoclonal antibody targeting VEGF-A, received FDA approval in 2004 for first-line treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy, marking the first anti-angiogenic therapy for solid tumors.^[77] Subsequent approvals expanded its use to other malignancies, including non-small cell lung cancer, renal cell carcinoma, and glioblastoma, often enhancing chemotherapy outcomes by reducing tumor vascularization.^[78] In ophthalmology, ranibizumab (Lucentis), a Fab fragment derived from the same parent antibody as bevacizumab, was approved by the FDA in 2006 for neovascular (wet) age-related macular degeneration (AMD), where intravitreal administration inhibits VEGF-A-induced choroidal neovascularization and leakage.^[79] Aflibercept (Eylea), a fusion protein acting as a soluble decoy receptor that traps VEGF-A and placental growth factor (PlGF), gained FDA approval in 2011 for wet AMD and later for macular edema following retinal vein occlusion, offering prolonged inhibition compared to monoclonal antibodies.^[80] These agents have shown significant improvements in progression-free survival in cancer and visual acuity in ocular diseases.^[81] More recently, as of 2025, bispecific antibodies like faricimab, which inhibit both VEGF-A and angiopoietin-2, have been approved for ocular diseases, offering potentially longer-lasting effects and reduced injection frequency.^[82] Pro-angiogenic approaches leverage recombinant VEGF-A, particularly the VEGF165 isoform, to promote vessel formation in ischemic tissues. Phase I and II clinical trials in the 1990s and 2000s using naked-plasmid or adenoviral delivery of VEGF165 for critical limb ischemia (CLI) demonstrated safety and modest improvements in perfusion, ulcer healing, and limb salvage rates in patients with peripheral artery disease unresponsive to revascularization.^[83] For instance, intramuscular injections led to increased ankle-brachial indices and collateral vessel development, though results varied due to delivery inefficiencies and transient expression.^[84] Similar trials for ischemic heart disease, including direct intramyocardial VEGF gene therapy, aimed to enhance coronary collateralization but yielded limited success, often failing primary endpoints like improved myocardial perfusion owing to the formation of immature, leaky vessels lacking proper maturation.^[85] Delivery methods for anti-VEGF therapies are tailored to disease localization: intravitreal injections are standard for ophthalmologic indications like diabetic retinopathy and wet AMD, administered monthly or as needed to achieve localized suppression with minimal systemic exposure.^[86] Systemic intravenous administration predominates in oncology, allowing broad distribution to metastatic sites but increasing the risk of class-wide side effects such as hypertension, proteinuria, and thrombotic events due to VEGF-A inhibition in normal vasculature.^[87] These adverse effects arise from disrupted endothelial integrity and renal filtration, with hypertension occurring in up to 20-30% of patients on systemic therapy and proteinuria in 20-50%, necessitating monitoring.^[88] Approved indications underscore the clinical impact of VEGF-A modulation: in oncology, anti-VEGF agents like bevacizumab are endorsed for multiple cancers including ovarian and cervical, typically combined with chemotherapy to extend survival.^[75] In ophthalmology, they are first-line for wet AMD, diabetic macular edema, and myopic choroidal neovascularization, with ranibizumab and aflibercept leading to significant improvements in visual acuity and stabilization in the majority of treated patients.^[89] However, pro-angiogenic VEGF therapies remain unapproved for routine use in ischemic heart disease due to inconsistent efficacy and concerns over vascular immaturity, which can lead to hemorrhage or insufficient hemodynamic benefits.^[90]

Recent Research and Developments

Advances in Therapies

Recent advances in VEGF-A-targeted therapies have focused on innovative delivery methods and combination strategies to enhance efficacy while mitigating resistance in conditions such as refractory angina, ocular diseases, and cancers. Gene therapy approaches using viral vectors to deliver VEGF-A have shown promise in improving myocardial perfusion in patients with refractory angina. In the phase II EXACT trial completed in 2024, intramyocardial delivery of XC001—an adenoviral vector expressing multiple VEGF isoforms—resulted in a reduction of total myocardial perfusion deficit by 10.2% at 3 months, 14.3% at 6 months, and 10.2% at 12 months, alongside improvements in exercise duration (up to 115.5 seconds) and reduced angina episodes (by up to 8.8 per week).^[91] Similarly, the ongoing phase II ReGenHeart trial (NCT03039751), with phase 2 design published in 2024, evaluates AdVEGF-D gene transfer via catheter-mediated delivery to confirm safety and symptom relief in refractory angina patients. Prior phase 1/2a data support neoangiogenesis without major adverse events.^[92] Novel inhibitors targeting VEGF-A alongside complementary pathways have expanded treatment options for neovascular age-related macular degeneration (AMD). Faricimab, a bispecific antibody inhibiting both VEGF-A and angiopoietin-2 (Ang-2), received FDA approval in 2022 for wet AMD and diabetic macular edema, enabling extended dosing intervals of up to 16-20 weeks compared to prior anti-VEGF monotherapies, thereby reducing injection frequency and improving patient adherence.^[93] Real-world studies in 2024-2025 have corroborated these benefits, showing sustained anatomic improvements and fewer visits in treatment-resistant cases.^[94] Delivery innovations, including nanoparticles and hydrogels, have enabled sustained VEGF-A release for applications in wound healing and ischemia. In 2024 studies, VEGF-loaded photo-crosslinked hydrogels promoted angiogenesis in scratch wound assays, accelerating re-epithelialization and vascularization in preclinical wound models (e.g., full-thickness excisional wounds in mice) by providing controlled release over weeks.^[95] Lipid nanoparticles encapsulating VEGFA mRNA have similarly enhanced wound closure rates to near-complete healing (average 2.4% residual area at 14 days) in preclinical diabetic wound models, offering localized, non-viral alternatives to traditional gene therapy.^[96] Combination therapies integrating VEGF-A inhibitors with immunotherapy have yielded significant regulatory milestones in gynecologic cancers. The FDA approved pembrolizumab plus lenvatinib—a multi-kinase inhibitor targeting VEGFR2 and other VEGF pathways—in 2021 for advanced endometrial carcinoma following prior systemic therapy, based on phase II/III data showing prolonged progression-free survival (median 7.2 months vs. 3.8 months) and overall survival benefits in mismatch repair proficient tumors.^[97] These regimens address tumor microenvironment remodeling by simultaneously blocking angiogenesis and enhancing T-cell infiltration. Therapeutic resistance to VEGF-A inhibitors often arises through upregulation of alternative angiogenic pathways, such as fibroblast growth factor (FGF), prompting strategies to monitor and counteract these mechanisms. Preclinical and clinical evidence indicates that FGF/FGFR activation compensates for VEGF blockade, contributing to tumor escape in resistant cases.^[98] Circulating VEGF levels and soluble VEGFRs serve as key biomarkers for predicting response and resistance, with elevated baseline VEGF correlating to poorer outcomes and guiding dose adjustments in ongoing trials.^[57] A 2025 review highlights progress in enhanced VEGFR2 inhibitors designed for tumor-specific delivery, reducing off-target toxicity through targeted conjugates like bispecific antibodies or nanobody-fused lentiviral vectors. These approaches, such as PD-L1/VEGFR2 bispecifics, selectively inhibit endothelial VEGFR2 in tumor vasculature while sparing normal tissues, demonstrating delayed tumor growth and improved survival in preclinical models without systemic hypertension.^[99]

Emerging Roles and Challenges

Vascular endothelial growth factor A (VEGF-A) plays a pivotal role in promoting adult hippocampal neurogenesis, where it acts as a key regulator of neural stem cell proliferation and differentiation in response to environmental stimuli such as exercise. Studies have demonstrated that VEGF-A signaling is essential for the maintenance of the neural stem cell niche in the hippocampus, facilitating the integration of new neurons into existing circuits. For instance, conditional knockout of VEGF-A in neural progenitors leads to reduced neurogenesis and impaired cognitive function. In the context of neurodegeneration, recent 2024 research has linked dysregulated VEGF-A expression to Alzheimer's disease progression through compromised blood-brain barrier (BBB) integrity, where diminished VEGF-A-mediated endothelial tight junction maintenance exacerbates amyloid-beta accumulation and neuroinflammation. Single-nucleus transcriptomic analyses of human brain tissue from Alzheimer's patients reveal that VEGF-A downregulation in cerebrovascular endothelial cells correlates with early BBB leakage, highlighting its protective role against vascular dysfunction in the disease.^[100]^[101]^[102]^[103] Beyond neurological functions, VEGF-A contributes to inflammatory responses in severe COVID-19, where elevated circulating levels drive pulmonary vascular permeability and endothelial dysfunction, exacerbating acute respiratory distress syndrome. Analyses from 2023 cohorts of critically ill patients show that VEGF-A concentrations are significantly higher in non-survivors, correlating with markers of lung injury and coagulopathy, as SARS-CoV-2-induced hypoxia amplifies VEGF-A release from infected endothelial cells. In metabolic disorders, VEGF-A modulates adipose tissue angiogenesis during obesity, promoting vascular remodeling to support expanding fat depots; however, chronic overexpression can lead to dysfunctional vessels and insulin resistance, as evidenced by mouse models where adipose-specific VEGF-A enhancement alters beiging and energy expenditure. Similarly, in diabetic nephropathy, heightened glomerular VEGF-A expression fosters hyperpermeability and mesangial expansion, with serum levels serving as a predictive biomarker for progression to end-stage renal disease in type 2 diabetes patients.^[104]^[105]^[106]^[107]^[108]^[109] Key challenges in VEGF-A research include the incomplete elucidation of isoform-specific therapeutic targeting, as VEGF-A exists in multiple splice variants (e.g., VEGF-A165a vs. VEGF-A165b) with opposing pro- and anti-angiogenic effects, complicating selective inhibition without off-target vascular disruption. Additionally, developing robust models for anti-angiogenic resistance remains critical, since clinical resistance often arises from compensatory pathways like stromal cell activation or vessel co-option, independent of VEGF-A blockade, as observed in tumor xenograft studies. Future directions leverage single-cell RNA sequencing to uncover cell-type-specific VEGF-A responses, revealing heterogeneous signaling in endothelial subpopulations during hypoxia or inflammation, which could inform personalized interventions. Ethical concerns in embryonic studies involving VEGF-A manipulation, particularly in human embryonic stem cell models for vasculogenesis, center on risks of teratogenic effects and the moral implications of altering developmental angiogenesis pathways. As of 2025, emerging insights underscore VEGF-A's involvement in climate-related hypoxia adaptations, such as blunted responses in high-altitude populations like Sherpas, where genetic variants in the VEGFA promoter attenuate excessive angiogenesis to enhance oxygen efficiency under chronic low-oxygen conditions.^[110]^[57]^[111]^[112]^[113]^[114]^[115]^[116]^[117]

References

[1]
VEGFA vascular endothelial growth factor A [ (human)] - NCBI
Sep 14, 2025 · This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer.
[2]
The vascular endothelial growth factor (VEGF) family
Vascular endothelial growth factors (VEGFs) are a family of secreted polypeptides with a highly conserved receptor-binding cystine-knot structure.
[3]
Structure and function of vascular endothelial growth factor and its ...
The VEGF-VEGFR system plays a central role in the regulation of tumor angiogenesis and can be a potential target for anti-angiogenic therapy. There are five ...
[4]
A Structural Overview of Vascular Endothelial Growth Factors ...
The vascular endothelial growth factor A (VEGF-A) is the main factor responsible for endothelial cell migration, proliferation and tube formation, and other ...
[5]
192240 - VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA
(1996) reported the localization of the VEGF gene to chromosome 6p12 by FISH. Vincenti et al. (1996) also used in situ hybridization to map the VEGF gene to ...<|control11|><|separator|>
[6]
VEGF-A splicing: the key to anti-angiogenic therapeutics? - PMC - NIH
VEGF-A spans 16,272 bp of chromosome 6p12 and consists of eight exons. Alternate 5′ and 3′ splice site selection in exons 6, 7 and 8 generate multiple isoforms.
[7]
and anti-angiogenic isoforms of VEGF is differentially regulated by ...
Oct 15, 2008 · It is widely accepted that alternative splicing of VEGF, which results in the conventional pro-angiogenic family, is fundamental to the ...
[8]
RNA-Sequencing data supports the existence of novel VEGFA ...
Mar 3, 2017 · A second set of anti-angiogenic isoforms termed VEGFAxxxb that utilise an alternative splice site in the final exon have been widely reported, ...Results · Sequencing Of Rt-Pcr... · Rna-Seq Analysis Of Cells...
[9]
A hypoxia response element in the Vegfa promoter is required for ...
HIF-1 is thought to be a major regulator of Vegfa expression in several cell types, and acts via a well-characterized HRE in the Vegfa promoter [6, 17]. However ...
[10]
Vegfa promoter gene hypermethylation at HIF1α binding site is an ...
Apr 22, 2021 · Hypermethylation of the Vegfa promoter gene at the HIF1α binding site was found, since early stages of the CKD progression.
[11]
Hypoxic induction of vascular endothelial growth factor regulates ...
Aug 11, 2011 · Its expression is commonly regulated by hypoxia-inducible factors (HIF) that are functionally induced in low-oxygen conditions and that activate ...
[12]
Vascular Endothelial growth factor signaling in hypoxia and ...
Hypoxia-induced changes at the transcriptome and inflammation-induced cytokine/chemokine responses modulate endothelial cells and innate immune cells.
[13]
Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial ...
Oct 20, 2020 · Under hypoxic conditions, VEGFA derived from PMCs acts on VEGFR1 of GC cells, resulting in p-ERK/p-JNK pathway activation, increased integrin α ...Missing: patterns | Show results with:patterns
[14]
Systemic hypoxia changes the organ-specific distribution of vascular ...
Under hypoxic conditions, however, VEGF expression was strongly increased in glial cells (Figs. 3 b and d and 7f), and was now also detectable in neuronal ...
[15]
The vascular endothelial growth factor (VEGF) family: angiogenic ...
Feb 1, 2005 · This paper and [42] demonstrate that loss of a single VEGF-A allele causes embryonic lethality. Article PubMed CAS Google Scholar. Ferrara N ...Missing: ortholog | Show results with:ortholog
[16]
Heterozygous embryonic lethality induced by targeted inactivation of ...
Here we report the unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12.Missing: evolutionary conservation ortholog
[17]
Vegfa MGI Mouse Gene Detail - vascular endothelial growth factor A
Hetero- or homozygous null mutants show embryonic lethality with impaired angiogenesis and blood-island formation. Mutants selectively expressing isoform ...Missing: evolutionary | Show results with:evolutionary
[18]
The crystal structure of vascular endothelial growth factor (VEGF ...
VEGF is a glycosylated, disulfide-linked homodimer and is expressed in different isoforms ranging in size from 121 to 206 residues in humans (VEGF121, VEGF ...
[19]
https://www.sciencedirect.com/science/article/pii/S0969212697002840
[20]
Enhanced secretion of biologically active, non-glycosylated VEGF ...
Apr 15, 2013 · VEGF is a homodimeric glycoprotein that contains one N-glycosylation site ... VEGF, a finding not previously reported. Our findings suggest that S ...
[21]
Molecular Pharmacology of VEGF-A Isoforms: Binding and ... - MDPI
The human Vegfa gene is located on chromosome 6p21.1 [52], with a coding region spanning approximately 14 kilobases consisting of eight exons and seven introns.
[22]
Crystal structure at 1.7 A resolution of VEGF in complex with domain ...
Nov 28, 1997 · Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor ... PDB/1FLT.
[23]
The vascular endothelial growth factor (VEGF) isoforms
Oct 13, 2017 · VEGF121 is a nonheparin-binding acidic protein, which is freely diffusible. The longer forms, VEGF189 or VEGF206, are highly basic proteins ...
[24]
Molecular Diversity of VEGF-A as a Regulator of Its Biological Activity
The VEGF gene resides on chromosome 6 [167] and is organized as a single gene consisting of eight exons spanning approximately 14 kbp and separated by 7 introns ...
[25]
The Emerging Role of the Antiangiogenic VEGF165b Splice Variant
The main proangiogenic and antiangiogenic isoforms are VEGF165 and VEGF165b, respectively. The proangiogenic isoforms encode a terminal 6–amino acid ...
[26]
VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits ...
Mar 18, 2008 · These results show that the balance of antiangiogenic to proangiogenic isoforms switches to a variable extent in CRC, regulates tumour growth rates and affects ...
[27]
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular ...
VEGF levels must be highly regulated during development, as either a two-fold gain or 50%-loss of VEGF expression results in lethal cardiovascular complications ...
[28]
Vascular Endothelial Growth Factor Isoform Expression as a ...
A, VEGF RT-PCR showing that VEGF121 is the predominant isoform expressed in both early-stage and advanced melanoma cell lines.
[29]
Differential Expression of VEGF 121 , VEGF 165 and VEGF 189 in ...
VEGF121 was the most abundant isoform in all tested tissues, whereas VEGF165 exhibited lower levels, and VEGF189 only very small amounts of transcript.Missing: properties | Show results with:properties
[30]
Arteriolar and venular patterning in retinas of mice selectively ...
In contrast, VEGF120/120 mice exhibited severe defects in vascular outgrowth and patterning, whereas VEGF188/188 mice displayed normal venular outgrowth but ...
[31]
Spatially restricted patterning cues provided by heparin-binding ...
We conclude that differential VEGF-A isoform localization in the extracellular space provides a control point for regulating vascular branching pattern.
[32]
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis in vivo.
[33]
Molecular Bases of VEGFR-2-Mediated Physiological Function and ...
Functional sites and motifs in VEGFR2. In the human VEGFR-2, there are 18 N-linked glycosylation sites, 15 phosphorylation sites, and many ATP binding sites ...
[34]
Heterozygous embryonic lethality induced by targeted inactivation of ...
Apr 4, 1996 · Here we report the unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12. Angiogenesis and ...
[35]
Abnormal blood vessel development and lethality in embryos ...
Apr 4, 1996 · Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF +/- ) embryos.
[36]
The Role of Vascular Endothelial Growth Factor in Wound Healing
Hypoxia upregulates tissue expression of VEGF and its receptors, which in turn promote an angiogenic response. Hypoxia, through hypoxia inducible factor (HIF)- ...
[37]
Molecular Mechanisms of VEGF-A Action during Tissue Repair
Following mechanical injury, VEGF-A expression is upregulated in epidermal keratinocytes at the wound edges and infiltrating macrophages/neutrophils; induction ...
[38]
VEGF guides angiogenic sprouting utilizing endothelial tip cell ...
We show here that VEGF-A controls angiogenic sprouting in the early postnatal retina by guiding filopodial extension from specialized endothelial cells.
[39]
Vascular Endothelial Growth Factor Induces ... - PubMed Central - NIH
We conclude that VEGF in the presence of a basal lamina-type extracellular matrix specifically induces fenestrations in endothelial cells.
[40]
Vascular endothelial growth factor induces VE-cadherin tyrosine ...
Jul 1, 1998 · In this study we have shown that VEGF induces a strong increase in tyrosine phosphorylation of the adherens junction components VE-cadherin, β- ...
[41]
The vascular endothelial growth factor (VEGF) system as a key ...
Mar 26, 2023 · The production of VEGF by secondary follicles stimulates preantral follicular development by directly affecting follicular cells and promoting ...<|control11|><|separator|>
[42]
Role of Vascular Endothelial Growth Factor (VEGF) in Human ...
Feb 10, 2021 · VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. Embo Mol. Med. 2013;5:1415–1430 ...
[43]
Vascular endothelial growth factor: Direct neuroprotective effect in in ...
Our results indicate that VEGF acts through VEGFR-2 receptors and PI3-K to reduce cell death from hypoxia and glucose deprivation in cultured HN33 cells.Missing: maintenance | Show results with:maintenance
[44]
Osteoblast-derived VEGF regulates osteoblast differentiation and ...
Osteoblast-derived VEGF is important for bone development and postnatal bone homeostasis. Previous studies have demonstrated that VEGF affects bone repair ...
[45]
Vascular endothelial growth factor enhances glomerular capillary ...
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis · Authors.
[46]
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in ...
Macrophages can be recruited to sites of inflammation by VEGF-A via VEGFR1 interactions (27, 28), and activated macrophages are known to express a variety ...
[47]
Insufficient VEGFA activity in yolk sac endoderm ... - PubMed
Vascular endothelial growth factor A (VEGFA) plays a pivotal role in the first steps of endothelial and haematopoietic development in the yolk sac, ...Missing: valve | Show results with:valve
[48]
Vascular endothelial growth factor receptor signaling is required for ...
Sep 16, 2005 · Hence, high levels of VEGF, especially at the onset of EMT, inhibit valve development, but too little VEGF signaling, especially at later points ...
[49]
Full article: VEGF-A121a binding to Neuropilins – A concept revisited
VEGF-A165a binds NRP1 with higher affinity than to NRP2 (kd ∼100–300 pM for NRP1,, ∼700 pM for NRP2; as noted in the previous section, the measured cell surface ...
[50]
The Role of Heparan Sulfate and Neuropilin 2 in VEGFA Signaling ...
VEGFR2 can interact with VEGFR2 co-receptors such as heparan sulfate proteoglycans (HSPGs) and neuropilin 2 (NRP2), but the exact roles of these co-receptors, ...
[51]
Structural determinants of growth factor binding and specificity by ...
Jan 22, 2010 · All VEGF-A isoforms bind to VEGFR-1 and VEGFR-2, whereas PlGF and ... induces dimerization of the extracellular domain of VEGFR-2 (34).
[52]
VEGF-A splice variants bind VEGFRs with differential affinities - PMC
Sep 2, 2020 · We found that VEGF-A121 also binds VEGFR1 with an affinity KD = 3.7 nM. We further demonstrated that the anti-angiogenic variant, VEGF-A165b ...
[53]
VEGFR-1 and VEGFR-2: two non-identical twins with a unique ...
Both VEGFR-1 and VEGFR-2 are expressed by endothelial cells, suggesting that under a favorable condition such as availability of appropriate ligand, VEGFR-1 may ...
[54]
Signaling of vascular endothelial growth factor receptor-1 tyrosine ...
Sep 15, 2006 · We and others have recently shown that VEGFR-1 is expressed not only in vascular endothelial cells but also in monocytes/macrophages,11,12 and ...Signals From Vegfr-1 Tk... · Vegfr Tk Inhibitor, Krn951... · Vegfr-1 Is Closely...
[55]
Vascular endothelial growth factor signaling in health and disease
May 19, 2025 · This review provides a comprehensive overview of VEGF ligands and receptors, elucidating their molecular mechanisms and regulatory networks.
[56]
VEGF-A/VEGFR2 signaling network in endothelial cells relevant to ...
Sep 12, 2016 · We have developed the first comprehensive map of endothelial cell-specific signaling events of VEGFA/VEGFR2 system pertaining to angiogenesis.
[57]
VEGFR1 promotes cell migration and proliferation through PLCγ ...
Dec 19, 2017 · We show empirically that VEGFR1 promotes macrophage migration through PLC γ and PI3K pathways and promotes macrophage proliferation through a PLC γ pathway.Missing: chemotaxis | Show results with:chemotaxis
[58]
Endothelial Cell Migration During Angiogenesis | Circulation Research
Mar 30, 2007 · A, The formation of stress fibers by binding of VEGF to VEGFR-2 requires a cooperative interaction between VEGFR-2 and integrins, especially ...
[59]
PTEN modulates vascular endothelial growth factor ... - PubMed
The tumor suppressor PTEN has been shown to down-regulate phosphatidylinositol 3-kinase signaling, yet the effects of PTEN on VEGF-mediated signaling and ...
[60]
Positive and Negative Regulation of Angiogenesis by Soluble ...
Apr 27, 2018 · Soluble VEGFR-1 isoforms, either sVEGFR-1 or soluble fms-like tyrosine kinase (sFlt)1-14, act as “VEGF sinks”. By binding members of the VEGF ...Missing: PTEN | Show results with:PTEN
[61]
The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor ...
The clinical importance of VEGF for tumor growth is supported by the fact that most tumors produce VEGF and that the inhibition of VEGF-induced angiogenesis ...
[62]
The impact of VEGF on cancer metastasis and systemic disease
VEGFs augment cancer metastasis through several mechanisms, including (1) Stimulation of tumor angiogenesis; (2) Formation of leaky and disorganized primitive ...
[63]
VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration
May 22, 2025 · In DR, VEGF promotes retinal neovascularization and intraretinal fluid accumulation, leading to complications like diabetic macular edema (DME) ...Missing: ocular | Show results with:ocular
[64]
Vascular Endothelial Growth Factor A in Intraocular Vascular Disease
In patients with neovascular AMD, VEGF inhibition is associated with preservation of visual acuity and in many cases clinically significant visual acuity gain ( ...
[65]
Vascular Endothelial Growth Factor (VEGF) Expression in Human ...
These results demonstrate distinct expression of VEGF and its receptors (flt-1 and Flk-1) in atherosclerotic lesions in human coronary arteries.
[66]
Vascular Endothelial Growth Factor (VEGF) and Its Role in the ... - NIH
May 10, 2024 · Furthermore, VEGF is considered a potential biomarker for collateral circulation assessment and heart failure (HF) mortality. Additionally, as ...
[67]
Circulating Angiogenic Factors and the Risk of Preeclampsia
... sFlt-1 and the decrease in the levels of proangiogenic VEGF and PlGF. In women with preeclampsia, sFlt-1 appears to increase earlier in gestation and to ...
[68]
Effect of vascular endothelial growth factor gene polymorphisms on ...
Dec 20, 2021 · This study aimed to investigate the impact of a common genetic polymorphism in the VEGF gene on disease activity and synovial lesions in patients with RA
[69]
Raised VEGF: High sensitivity and specificity in the diagnosis ... - NIH
Aug 15, 2018 · This study provides class IV evidence that elevated sVEGF levels accurately identifies patients with POEMS syndrome. Polyneuropathy, ...
[70]
Multiple Variants in Vascular Endothelial Growth Factor (VEGFA ...
Aug 1, 2007 · CONCLUSIONS—These data demonstrate that multiple VEGFA variants are associated with the development of severe retinopathy in type 1 diabetes.Missing: mutations | Show results with:mutations
[71]
Mutations in VEGFA are associated with congenital left ventricular ...
May 28, 2010 · In this study, we identified three exon mutations in the VEGFA gene in three of 192 nonsyndromic LVOTO patients, and the overall mutation ...
[72]
Blood-based biomarkers of cerebral small vessel disease
In the community-based Framingham Study, higher VEGF-A levels were shown to be associated with an increased risk of incident stroke/transient ischemic attack ...
[73]
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of ...
Bevacizumab (Avastin®), a VEGF-A targeting monoclonal antibody, was the first approved angiogenesis inhibitor. •. Approved in a range of solid tumor indications ...
[74]
Anti-VEGF Treatments - American Academy of Ophthalmology
Jul 26, 2023 · Anti-VEGF medicine blocks VEGF, slowing the growth of blood vessels in the eye. This slows or stops damage from the abnormal blood vessels and ...
[75]
[PDF] FDA PI1
Bevacizumab binds VEGF and prevents the interaction of VEGF to its. 55 ... The efficacy of AVASTIN as a single agent in colorectal cancer has not. 147.
[76]
FDA Approves First Angiogenesis Inhibitor To Treat Colorectal Cancer
Feb 27, 2004 · The FDA has approved Avastin (bevacizumab) as a first-line treatment for patients with metastatic colorectal cancer -- cancer that has spread to ...
[77]
Lucentis (ranibizumab) FDA Approval History - Drugs.com
Jun 30, 2006, Approval FDA Approves Lucentis (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration. Dec 30, 2005, Genentech Submits Biologics ...
[78]
[PDF] EYLEA (afilbercept) injection Label - accessdata.fda.gov
EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular. Degeneration (AMD). 2. DOSAGE AND ADMINISTRATION. 2.1. General ...
[79]
Regeneron Announces FDA Approval of EYLEA (aflibercept ...
Nov 18, 2011 · EYLEA acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation ...
[80]
Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia
Clinically, VEGF gene therapy provides inconsistent findings. Phase I clinical trials demonstrated that naked-plasmid VEGF165 gene therapy is safe and ...
[81]
Angiogenic Gene Therapy for Experimental Critical Limb Ischemia
Early clinical studies on gene transfer of angiogenic growth factors, including vascular endothelial growth factor (VEGF), suggest a possible strategy to treat ...Missing: trials | Show results with:trials
[82]
VEGF gene therapy fails to improve perfusion of ischemic ... - PubMed
Apr 7, 2009 · VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.Missing: immature | Show results with:immature
[83]
Ranibizumab - StatPearls - NCBI Bookshelf - NIH
[8] Ranibizumab was first FDA-approved in 2006 for the treatment of NVAMD. Later, it was approved to treat the following conditions discussed below. FDA ...
[84]
Systemic Adverse Events Among Patients With Diabetes Treated ...
Jun 1, 2023 · Systemic anti-VEGF therapy has been associated with an increase in the risk of several adverse events, including hypertension and arterial ...
[85]
Systemic Effects of Intravitreal Anti-VEGF Therapy - PubMed Central
Jun 6, 2025 · This damage may lead to impaired kidney filtration, proteinuria, hypertension, and thrombotic microangiopathy [36]. The cumulative evidence ...
[86]
Anti-vascular endothelial growth factor indications in ocular disease
The anti-VEGF therapy is now commonly used for a wide range of pathologies like age-related macular degeneration, retinal vein occlusion or diabetic retinopathy ...
[87]
VEGF Gene Therapy Fails to Improve Perfusion of Ischemic ... - NIH
Despite the promise of proangiogenic gene therapy most clinical trials have failed to show benefit for the primary end point analysis.Missing: immature | Show results with:immature
[88]
Angiogenic Gene Therapy for Refractory Angina: Results of the ...
May 2, 2024 · In this single-arm, multicenter, open-label trial, 32 patients with no option refractory angina received a single treatment of XC001 (1×1011 ...Missing: AAV- | Show results with:AAV-
[89]
rationale and design of the phase 2 ReGenHeart trial | Open Heart
Oct 17, 2024 · The phase 2 ReGenHeart trial will provide knowledge of the safety and efficacy of AdVEGF-D GT to ameliorate symptoms in refractory angina patients.Missing: AAV- | Show results with:AAV-
[90]
Press Releases | Friday, Jan 28, 2022 - Genentech
Jan 28, 2022 · Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic ...
[91]
Real world outcomes of faricimab in treatment resistant neovascular ...
Sep 29, 2025 · Faricimab is a bispecific antibody designed to simultaneously inhibit both VEGF-A and Ang-2. This dual mechanism of action is thought to address ...
[92]
Photo-Crosslinked Pro-Angiogenic Hydrogel Dressing for Wound ...
Sep 15, 2024 · To test whether the VEGF-loaded hydrogel provides angiogenic functionality, we performed the scratch wound healing assay using human umbilical ...
[93]
Efficient Delivery of VEGFA mRNA for Promoting Wound Healing via ...
Aug 6, 2025 · It was found that LNP/VEGF-A mRNA nanoparticles treated wounds were almost healed after 14 days with an average wound area of 2.4%, compared ...
[94]
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab ... - Eisai
Oct 20, 2025 · LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma ...
[95]
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer ...
Apr 1, 2021 · Upregulation of alternative angiogenic factors, including FGF, plays a vital role in the induction of resistance to VEGF/VEGFR inhibitors.
[96]
Transient intracellular expression of PD-L1 and VEGFR2 bispecific ...
Apr 19, 2025 · PD-L1, an immune checkpoint inhibitor, and VEGFR2, essential for cancer metastasis, play pivotal roles in tumorigenesis.
[97]
Diverse roles for VEGF-A in the nervous system | Development
Apr 15, 2012 · Two independent studies demonstrated that VEGF-A directly regulates the migration of differentiated neurons, independently of its roles in ...Missing: original | Show results with:original
[98]
Autocrine VEGF drives neural stem cell proximity to the adult ...
Apr 17, 2024 · We recently found that adult hippocampal NSCs express VEGF, a soluble factor with chemoattractive properties for vascular endothelia. Here, we ...
[99]
A single nuclear transcriptomic characterisation of mechanisms ...
Mar 12, 2024 · Brain perfusion and blood-brain barrier (BBB) integrity are reduced early in Alzheimer's disease (AD). We performed single nucleus RNA ...
[100]
Association of ten VEGF family genes with Alzheimer's disease ...
Dec 6, 2024 · In fact, evidence is already emerging that demonstrates CNS angiogenesis can be regulated through VEGF-dependent signaling at the BBB.
[101]
Vascular Endothelial Growth Factor as Potential Biomarker for ... - NIH
Jul 13, 2023 · In COVID-19 patients VEGF can contribute to the prediction of necessity of ICU, mortality and the prediction of ARDS, kidney injury or shock.Missing: leak | Show results with:leak
[102]
friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections?
This review article discusses the role of vascular endothelial growth factor A (VEGF-A) in the pathogenesis of SARS-CoV-2 and HIV infection.
[103]
Angiogenesis in Adipose Tissue: The Interplay Between ... - Frontiers
Feb 8, 2021 · Overexpression of VEGF in WAT and BAT in mice led to increased number and size of blood vessels, increased insulin sensitivity, and improved ...Abstract · Introduction · Angiogenesis in Healthy... · Angiogenesis in Obesity
[104]
Obesity Alters the Vascular Morphology and VEGF‐A Signaling in ...
May 19, 2025 · Obesity alters cell geometry and vessel morphology in mice adipose tissue by increasing adipocyte size by 78% and reducing vessel density by 51%.
[105]
Serum VEGF as a predictive marker of glycemic control and diabetic ...
Multiple studies have reported a positive correlation between serum VEGF levels and DN in patients with type 1 and type 2 diabetes (9–12). Our study ...
[106]
VEGF-A: A Novel Mechanistic Link Between CYP2C-Derived EETs ...
Jan 20, 2023 · In fact, inhibiting VEGF-A using anti-VEGF or SU5416 markedly attenuated diabetes-induced glomerular injury through the inhibition of Nox4- ...
[107]
Trends and Challenges in Tumor Anti-Angiogenic Therapies - PMC
However, VEGF-A itself does not represent a single mature molecular species; it is a group of molecules appearing in several alternatively spliced isoforms.
[108]
Understanding and targeting resistance to anti-angiogenic therapies
Mechanisms of resistance to anti-angiogenic therapies can be broadly categorized into VEGF-axis dependent alterations, non-VEGF pathways, and stromal cell ...
[109]
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
May 11, 2023 · Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
[110]
scRNA-seq reveals that VEGF signaling mediates the response to ...
Apr 25, 2025 · scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer.
[111]
Single-cell RNA-sequencing implicates venous endothelial ... - bioRxiv
Dec 4, 2023 · In addition to VEGF-A signaling, the Wnt/β-catenin pathway is critical for both developmental angiogenesis and BBB formation and maintenance in ...
[112]
Ethical and Safety Issues of Stem Cell-Based Therapy - PMC - NIH
Ethical concerns include hESC research and iPSC cloning risks. Safety issues include undesired differentiation, malignant transformation, and potential tumor ...
[113]
The blunted vascular endothelial growth factor-A (VEGF-A ... - PeerJ
Aug 17, 2022 · The VEGF-A is highly expressed under hypoxia; its expression leads to endothelial cell proliferation and migration, thereby resulting in ...Missing: climate- | Show results with:climate-
[114]
The blunted vascular endothelial growth factor-A (VEGF-A ...
Aug 12, 2025 · We propose that the hypoxia-tolerant circulating VEGF-A level in Sherpa highlanders is linked with the genetic variations of VEGFA , ...Missing: climate- | Show results with:climate-